BRPI0416993A - partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas - Google Patents

partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas

Info

Publication number
BRPI0416993A
BRPI0416993A BRPI0416993-0A BRPI0416993A BRPI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A
Authority
BR
Brazil
Prior art keywords
particle
diagnostic
agent
pharmaceutical
preparation process
Prior art date
Application number
BRPI0416993-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Oskar Axelsson
Ib Leunbach
Magnus Karlsson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20035294A external-priority patent/NO20035294D0/no
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0416993A publication Critical patent/BRPI0416993A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/10—Metallic powder containing lubricating or binding agents; Metallic powder containing organic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
BRPI0416993-0A 2003-11-28 2004-11-26 partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas BRPI0416993A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20035294A NO20035294D0 (no) 2003-11-28 2003-11-28 Forbindelser
NO20044622 2004-10-26
PCT/NO2004/000364 WO2005051435A2 (en) 2003-11-28 2004-11-26 Tungsten particles as x-ray contrast agents

Publications (1)

Publication Number Publication Date
BRPI0416993A true BRPI0416993A (pt) 2007-02-06

Family

ID=34635761

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416993-0A BRPI0416993A (pt) 2003-11-28 2004-11-26 partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas

Country Status (10)

Country Link
US (1) US20070031339A1 (https=)
EP (1) EP1694366A2 (https=)
JP (1) JP4974222B2 (https=)
KR (1) KR101128577B1 (https=)
AU (1) AU2004292917A1 (https=)
BR (1) BRPI0416993A (https=)
CA (1) CA2547476A1 (https=)
MX (1) MXPA06006044A (https=)
RU (1) RU2361617C2 (https=)
WO (1) WO2005051435A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20052428D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Kontrastmidler
NO20052429D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Konstrastmidler
US8173166B2 (en) * 2005-09-09 2012-05-08 Honda Motor Co., Ltd. Methods of producing tungsten nanoparticles
US20070122620A1 (en) * 2005-11-02 2007-05-31 General Electric Company Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same
US9149545B2 (en) 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
US7977568B2 (en) 2007-01-11 2011-07-12 General Electric Company Multilayered film-nanowire composite, bifacial, and tandem solar cells
US8003883B2 (en) 2007-01-11 2011-08-23 General Electric Company Nanowall solar cells and optoelectronic devices
CN100565156C (zh) * 2007-02-09 2009-12-02 中国钢铁股份有限公司 混凝土结构物的裂缝检测方法
EP2296550B1 (en) 2008-07-07 2018-03-28 Koninklijke Philips N.V. K-edge imaging
US8591783B2 (en) 2008-11-23 2013-11-26 Medtronic, Inc. Medical devices with encapsulated visibility particles
WO2013022499A2 (en) * 2011-04-22 2013-02-14 Emory University Polymer coated metal particles and uses related thereto
WO2013034446A1 (en) * 2011-09-07 2013-03-14 Dahan Elodie An apparatus and method for generating useful energy
US9989482B2 (en) * 2016-02-16 2018-06-05 General Electric Company Methods for radiographic and CT inspection of additively manufactured workpieces
WO2017223343A1 (en) * 2016-06-22 2017-12-28 Board Of Regents, The University Of Texas System Contrast agents and methods of making the same for spectral ct that exhibit cloaking and auto-segmentation
JP2019128288A (ja) * 2018-01-25 2019-08-01 三井化学株式会社 きずの観察方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181626A (en) * 1977-12-27 1980-01-01 Ppg Industries, Inc. Method of preparing tungsten hexacarbonyl containing polymers and polymers prepared thereby
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
EP0580878B1 (en) * 1992-06-01 1996-01-10 BASF Aktiengesellschaft The use of dispersions of magneto-ionic particles as MRI contrast media
US5728590A (en) * 1994-07-29 1998-03-17 Nanoprobes, Inc. Small organometallic probes
RU2147243C1 (ru) * 1994-09-27 2000-04-10 Нюкомед Имагинг А/С Контрастное средство
US5759230A (en) * 1995-11-30 1998-06-02 The United States Of America As Represented By The Secretary Of The Navy Nanostructured metallic powders and films via an alcoholic solvent process
JP3411497B2 (ja) 1998-03-25 2003-06-03 科学技術振興事業団 Ｗ超微粒子とその製造方法、およびｗナノ結晶薄膜
FR2777016B1 (fr) 1998-04-06 2002-06-14 Rhone Poulenc Agrochimie Silicone azotee utile pour compacter les sequences d'acides nucleiques et utilisation pour la transfection
US6562330B1 (en) * 1998-11-13 2003-05-13 Biocompatibles Limited Therapeutic use of polymers
US6203778B1 (en) * 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
RU2173173C2 (ru) * 1999-05-12 2001-09-10 Институт химии твердого тела Уральского Отделения РАН Средство для контрастирования при рентгенодиагностике (варианты) и способ его получения
RU2172990C2 (ru) * 1999-06-01 2001-08-27 Валерий Иванович Печенкин Рентгенопоглощающий материал
US6869772B2 (en) 2000-03-10 2005-03-22 Washington University Method for labeling individual cells
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
ITVI20010126A1 (it) 2001-05-30 2002-11-30 Tecres Spa Cemento osseo radiopaco per uso ortopedico nonche' metodo di realizzazione
EP1443931B1 (en) 2001-07-20 2007-03-28 Iomed, Inc. Ocular iontophoretic device for delivering methotrexate based medicaments and use thereof to treat neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities
FR2830022B1 (fr) 2001-09-26 2004-08-27 Cime Bocuze Alliage base tungstene fritte a haute puissance
US6686308B2 (en) * 2001-12-03 2004-02-03 3M Innovative Properties Company Supported nanoparticle catalyst
WO2003075961A2 (en) * 2002-03-08 2003-09-18 James Hainfeld Gold nanoparticles used for x-rays imaging
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization

Also Published As

Publication number Publication date
RU2006117818A (ru) 2008-01-10
AU2004292917A1 (en) 2005-06-09
KR101128577B1 (ko) 2012-03-28
KR20060118515A (ko) 2006-11-23
WO2005051435A2 (en) 2005-06-09
JP2007512322A (ja) 2007-05-17
MXPA06006044A (es) 2006-09-04
EP1694366A2 (en) 2006-08-30
JP4974222B2 (ja) 2012-07-11
CA2547476A1 (en) 2005-06-09
US20070031339A1 (en) 2007-02-08
WO2005051435A3 (en) 2006-07-13
RU2361617C2 (ru) 2009-07-20

Similar Documents

Publication Publication Date Title
BRPI0416993A (pt) partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas
Ibraheem et al. Ciprofloxacin-loaded silver nanoparticles as potent nano-antibiotics against resistant pathogenic bacteria
Moosmann et al. Designer benzodiazepines: a new challenge
López-Galindo et al. Compositional, technical and safety specifications of clays to be used as pharmaceutical and cosmetic products
Exley Does antiperspirant use increase the risk of aluminium-related disease, including Alzheimer's disease?
Verma et al. Mechanistic insight into size-dependent enhanced cytotoxicity of industrial antibacterial titanium oxide nanoparticles on colon cells because of reactive oxygen species quenching and neutral lipid alteration
Melo et al. The role of nanomaterials in cosmetics: national and international legislative aspects
Pandya et al. Zeolite-based nanoparticles drug delivery systems in modern pharmaceutical research and environmental remediation
EA200601588A1 (ru) Стабилизированные перенасыщенные твёрдые растворы липофильных лекарственных средств
BR0111335A (pt) Derivado de quinazolina, processo para a preparação de um derivado de, quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
BR0309894A (pt) Composição, processo para preparar uma composição de celulose microcristalina, produto alimentìcio, composição farmacêutica, composição cosmética, forma de dosagem farmacêutica, e, composição industrial
BR0112903A (pt) Pó eletrostático
Pavani et al. Liquisolid technique based sustained release tablet of trimetazidine dihydrochloride
Rana et al. Bentonite in Korea: A resource and research focus for biomedical and cosmetic industries
Majhi et al. Coexistence of spheres and rods in micellar solution of dodecyldimethylamine oxide
Qasim et al. The effect of chitosan derived silver nanoparticles on mechanical properties, color stability of glass ionomer luting cements
Thakral et al. Quantification, mechanism, and mitigation of active ingredient phase transformation in tablets
Bucur et al. Potential health risk of microplastic exposures from skin-cleansing products
Larkin et al. Illuminating the health and safety of luminol
Scholz et al. Surface accumulation of Cerium, Self-Assembling peptide, and fluoride on sound bovine enamel
Goyanes et al. Chitosan–kaolin coprecipitate as disintegrant in microcrystalline cellulose-based pellets elaborated by extrusion–spheronization
Godek et al. Influence of zwitterionic CAPB on flocculation of the aqueous cationic guar gum/glauconite suspensions at various pH
HUP0303804A3 (en) Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them
Santhini et al. Nanomaterials and ethical issues
Gabriele et al. Efficacy of Chitosan-Carboxylic Acid Hydrogels in Reducing and Chelating Iron for the Removal of Rust from Stone Surface

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.